Compare RNGR & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNGR | IPSC |
|---|---|---|
| Founded | 2017 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 370.2M | 405.8M |
| IPO Year | 2017 | 2021 |
| Metric | RNGR | IPSC |
|---|---|---|
| Price | $15.79 | $2.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $20.00 | $4.25 |
| AVG Volume (30 Days) | 188.9K | ★ 2.0M |
| Earning Date | 04-27-2026 | 05-11-2026 |
| Dividend Yield | ★ 6.81% | N/A |
| EPS Growth | N/A | ★ 91.30 |
| EPS | ★ 0.12 | N/A |
| Revenue | N/A | ★ $109,164,000.00 |
| Revenue This Year | $23.86 | N/A |
| Revenue Next Year | $4.37 | N/A |
| P/E Ratio | $133.67 | ★ N/A |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $11.88 | $0.44 |
| 52 Week High | $18.82 | $2.97 |
| Indicator | RNGR | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 48.66 | 42.02 |
| Support Level | $15.62 | $1.91 |
| Resistance Level | $16.65 | $2.45 |
| Average True Range (ATR) | 0.45 | 0.13 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 33.33 | 9.31 |
Ranger Energy Services Inc offers high specification mobile rig well services, cased hole wireline services, and ancillary services in the U.S. oil and gas industry. Its services facilitate operations throughout the lifecycle of a well, including the completion, production, maintenance, intervention, workover, and abandonment phases. The company's reportable segments are: High Specification Rigs, Wireline Services, Processing Solutions and Ancillary Services. Maximum revenue is generated from the High Specification Rigs segment, which offers high specification well service rigs and complementary equipment and services to facilitate operations throughout the lifecycle of a well. The high specification rig services consist of well completion support, workovers, and well maintenance services.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.